Your browser doesn't support javascript.
loading
Dual and Opposite Costimulatory Targeting with a Novel Human Fusion Recombinant Protein Effectively Prevents Renal Warm Ischemia Reperfusion Injury and Allograft Rejection in Murine Models.
Guiteras, Jordi; De Ramon, Laura; Crespo, Elena; Bolaños, Nuria; Barcelo-Batllori, Silvia; Martinez-Valenzuela, Laura; Fontova, Pere; Jarque, Marta; Torija, Alba; Bestard, Oriol; Resina, David; Grinyó, Josep M; Torras, Joan.
Afiliación
  • Guiteras J; Experimental Nephrology Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
  • De Ramon L; Fundació Bosch i Gimpera, University of Barcelona, 08028 Barcelona, Spain.
  • Crespo E; Experimental Nephrology Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
  • Bolaños N; Experimental Nephrology Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
  • Barcelo-Batllori S; Experimental Nephrology Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
  • Martinez-Valenzuela L; Molecular Interactions Unit, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Scientific-Technical Services, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
  • Fontova P; Experimental Nephrology Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
  • Jarque M; Nephrology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
  • Torija A; Experimental Nephrology Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
  • Bestard O; Experimental Nephrology Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
  • Resina D; Experimental Nephrology Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
  • Grinyó JM; Nephrology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
  • Torras J; Faculty of Medicine, Bellvitge Campus, University of Barcelona, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Int J Mol Sci ; 22(3)2021 Jan 26.
Article en En | MEDLINE | ID: mdl-33530581
Many studies have shown both the CD28-D80/86 costimulatory pathway and the PD-1-PD-L1/L2 coinhibitory pathway to be important signals in modulating or decreasing the inflammatory profile in ischemia-reperfusion injury (IRI) or in a solid organ transplant setting. The importance of these two opposing pathways and their potential synergistic effect led our group to design a human fusion recombinant protein with CTLA4 and PD-L2 domains named HYBRI. The objective of our study was to determine the HYBRI binding to the postulated ligands of CTLA4 (CD80) and PD-L2 (PD-1) using the Surface Plasmon Resonance technique and to evaluate the in vivo HYBRI effects on two representative kidney inflammatory models-rat renal IRI and allogeneic kidney transplant. The Surface Plasmon Resonance assay demonstrated the avidity and binding of HYBRI to its targets. HYBRI treatment in the models exerted a high functional and morphological improvement. HYBRI produced a significant amelioration of renal function on day one and two after bilateral warm ischemia and on days seven and nine after transplant, clearly prolonging the animal survival in a life-sustaining renal allograft model. In both models, a significant reduction in histological damage and CD3 and CD68 infiltrating cells was observed. HYBRI decreased the circulating inflammatory cytokines and enriched the FoxP3 peripheral circulating, apart from reducing renal inflammation. In conclusion, the dual and opposite costimulatory targeting with that novel protein offers a good microenvironment profile to protect the ischemic process in the kidney and to prevent the kidney rejection, increasing the animal's chances of survival. HYBRI largely prevents the progression of inflammation in these rat models.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Recombinantes de Fusión / Daño por Reperfusión / Transducción de Señal / Trasplante de Riñón / Rechazo de Injerto Límite: Animals Idioma: En Revista: Int J Mol Sci Año: 2021 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Recombinantes de Fusión / Daño por Reperfusión / Transducción de Señal / Trasplante de Riñón / Rechazo de Injerto Límite: Animals Idioma: En Revista: Int J Mol Sci Año: 2021 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza